Biomarin Pharmaceutical (BMRN) Current Deferred Revenue (2009 - 2017)
Biomarin Pharmaceutical's (BMRN) quarterly Current Deferred Revenue came in at $17.4 million in Q3 2017, up 1669.54% on a QoQ basis from $985000.0 in Q4 2016.
Biomarin Pharmaceutical (BMRN) Current Deferred Revenue (2009 - 2017) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 5 years of Current Deferred Revenue data on file, last reported at $17.4 million in Q3 2017.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $17.4 million in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $17.4 million (changed N/A YoY) and the FY2016 annual result came in at $985000.0, changed N/A from the prior year.
- Current Deferred Revenue rose to $17.4 million in Q3 2017, from $985000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $17.4 million in Q3 2017 to a low of $985000.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 17.43 Mn |
| Dec 31, 2016 | 985,000.00 |
| Sep 30, 2012 | 1.08 Mn |
| Jun 30, 2012 | 1.11 Mn |
| Dec 31, 2011 | 342,000.00 |
| Dec 31, 2009 | 86,000.00 |